AB 343 - Arbutus Biopharma
Alternative Names: AB-343 - Arbutus Biopharma; Research programme: SARS-CoV-2 Mpro inhibitors - Arbutus Biopharma/Proteros Biostructures/X-Chem; Research programme: SARS-CoV-2 nsp5 main protease inhibitors - Arbutus Biopharma/Proteros Biostructures/X-ChemLatest Information Update: 19 Sep 2023
At a glance
- Originator Arbutus Biopharma; Proteros Biostructures; X-Chem
- Developer Arbutus Biopharma
- Class Antivirals; Small molecules
- Mechanism of Action Coronavirus 3C-like proteinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Coronavirus infections; COVID 2019 infections
Most Recent Events
- 11 Sep 2023 Discontinued - Preclinical for Coronavirus infections in Canada (PO) due to an unfavourable PK profile noted in the IND-enabling studies, and a potential nsp12 polymerase inhibitor
- 11 Sep 2023 Discontinued - Preclinical for COVID-2019 infections in Canada (PO) due to an unfavourable PK profile noted in the IND-enabling studies, and a potential nsp12 polymerase inhibitor
- 14 Mar 2023 Pharmacodynamics data from a preclinical trial in COVID-2019 infections released by Arbutus Biopharma